Clinical Trials Finder

Kidney Disease Clinical Trials: Recruiting Studies

Recruiting kidney disease clinical trials, listed from live ClinicalTrials.gov records with each trial's official title, phase, conditions, locations and a direct link to its full record.

These listings cover recruiting studies in kidney disease — including chronic kidney disease and kidney cancer research — exactly as the ClinicalTrials.gov records describe them. A listing here is not a recommendation: whether a trial could be relevant depends on your diagnosis, stage, treatment history and the trial's own eligibility criteria, which only the trial team can assess.

Trial data from ClinicalTrials.gov, fetched November 17, 2026 — always confirm details on the trial's own page.

Recruiting trials, most recently updated first

Showing the 20 most recently updated recruiting trials from a search that matched 1,864 records in total on the fetch date. The full, live list is on ClinicalTrials.gov.

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

NCT05917106 · Status: Recruiting · Phase: Not stated · Conditions: Carcinoma, Renal Cell Carcinoma, RCC, Kidney Neoplasms, Kidney Cancer · Last updated: 2026-11-17

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

1 study locations, none listed in the United States (including Nanjing, Jiangsu).

View this trial on ClinicalTrials.gov (NCT05917106)

Application Research of Hydromorphinone Sustained-release Tablets in the Treatment of Elderly Patients With Cancer Pain Accompanied by Renal Insufficiency

NCT07421674 · Status: Recruiting · Phase: Not stated · Conditions: Cancer Pain, Renal Insufficiency Chronic, Hydromorphone Use · Last updated: 2026-11-17

This clinical study aims to understand whether domestic hydromorphinone sustained-release tablets are effective and safe in treating moderate to severe cancer pain in elderly patients with renal insufficiency. It will also understand key safety concerns, especially regarding renal function and neurotoxicity. The main…

1 study locations, none listed in the United States (including Tai’an, Shandong).

View this trial on ClinicalTrials.gov (NCT07421674)

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

NCT06444815 · Status: Recruiting · Phase: Phase 1 · Conditions: Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma · Last updated: 2026-11-17

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given…

8 study locations, 8 in the United States (including Los Angeles, California; Orange, California; Miami, Florida).

View this trial on ClinicalTrials.gov (NCT06444815)

Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain

NCT07598448 · Status: Recruiting · Phase: Not stated · Conditions: Complement 3 Glomerulopathy · Last updated: 2026-11-17

This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.

5 study locations, none listed in the United States (including Las Palmas de Gran C, Las Palmas; Valencia, Valencia; Córdoba, Spain).

View this trial on ClinicalTrials.gov (NCT07598448)

An Open-Label, Adaptive Single-Dose Trial to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Afabicin

NCT07758608 · Status: Recruiting · Phase: Phase 1 · Conditions: Renal Impairment · Last updated: 2026-11-17

The primary purpose of this study is to assess the effect of renal impairment on the PK of afabicin desphosphono after a single oral 80 milligrams (mg) or intravenous (IV) 55 mg dose of afabicin.

1 study locations, none listed in the United States (including Berlin, Germany).

View this trial on ClinicalTrials.gov (NCT07758608)

Hematological Alterations Associated With the Use of Dipyrone Versus Paracetamol After Dental Extractions: a Double-blind, Randomized Clinical Trial

NCT07918040 · Status: Recruiting · Phase: Phase 4 · Conditions: Hematologic Test, Agranulocytosis, Side Effects, Blood Pressure Monitoring, Hepatic Complications, Renal Effects · Last updated: 2026-11-17

The goal of this clinical trial is to compare the safety of dipyrone and paracetamol when used for pain relief after dental extractions in adults. The study will focus on changes in blood cell counts and will also evaluate liver and kidney function and possible side effects. The main questions it aims to answer are: *…

1 study locations, none listed in the United States (including Juiz de Fora, Minas Gerais).

View this trial on ClinicalTrials.gov (NCT07918040)

A Phase 3b, Open-label, Single-arm, Patient Experience Study of Povetacicept Injection (Via Autoinjector) as Compared to Sibeprenlimab Injection (Via Prefilled Syringe) in Adults With Immunoglobulin A Nephropathy

NCT07890909 · Status: Recruiting · Phase: Phase 3 · Conditions: Immunoglobulin A Nephropathy · Last updated: 2026-11-17

The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy…

1 study locations, 1 in the United States (including Orlando, Florida).

View this trial on ClinicalTrials.gov (NCT07890909)

Carvedilol + Simvastatin vs. Carvedilol Alone for Chronic Liver Disease and Cirrhotic Cardiomyopathy and Its Impact on Hepatic Decompensation and Survival; a Double-blind Randomized Controlled Trial

NCT06431919 · Status: Recruiting · Phase: Not applicable · Conditions: Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Left Ventricular Diastolic Dysfunction, Acute Kidney Injury · Last updated: 2026-11-17

Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections. Rationale: Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and…

1 study locations, none listed in the United States (including Chandigarh, India).

View this trial on ClinicalTrials.gov (NCT06431919)

A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT06332755 · Status: Recruiting · Phase: Phase 1 · Conditions: Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma · Last updated: 2026-11-17

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109…

1 study locations, 1 in the United States (including Fairfax, Virginia).

View this trial on ClinicalTrials.gov (NCT06332755)

Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need

NCT07943143 · Status: Recruiting · Phase: Not applicable · Conditions: Localised or Metastatic Renal Cell Carcinoma · Last updated: 2026-11-17

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality…

1 study locations, none listed in the United States (including Hong Kong, Hong Kong).

View this trial on ClinicalTrials.gov (NCT07943143)

Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)

NCT07378514 · Status: Recruiting · Phase: Not stated · Conditions: Blood Clots, Infection and Inflammatory Reaction, Heart Disease, Kidney Disease, Vitamin K Antagonist, Diabetes, High Cholesterol, Liver Disease · Last updated: 2026-11-17

This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira…

1 study locations, none listed in the United States (including Glasgow, United Kingdom).

View this trial on ClinicalTrials.gov (NCT07378514)

A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

NCT07598396 · Status: Recruiting · Phase: Phase 2 · Conditions: Lupus, Systemic Lupus Erythematosus, Lupus Nephritis · Last updated: 2026-11-16

This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).

24 study locations, none listed in the United States (including CABA, Buenos Aires; Buenos Aires, Ciudad Autonoma Buenos Aires; Salvador, Estado de Bahia).

View this trial on ClinicalTrials.gov (NCT07598396)

An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

NCT06676527 · Status: Recruiting · Phase: Not stated · Conditions: Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases, Urogenital Diseases, Kidney Diseases, Urologic Diseases, Carcinoma, Renal Cell Cancer, Carcinoma, Renal Cell, Antineoplastic Agents · Last updated: 2026-11-16

This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and…

1 study locations, none listed in the United States (including Nanjing, Jiangsu).

View this trial on ClinicalTrials.gov (NCT06676527)

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT07188896 · Status: Recruiting · Phase: Phase 2 · Conditions: Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC) · Last updated: 2026-11-16

This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.

6 study locations, 6 in the United States (including Washington D.C., District of Columbia; Chapel Hill, North Carolina; Cleveland, Ohio).

View this trial on ClinicalTrials.gov (NCT07188896)

A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)

NCT07085728 · Status: Recruiting · Phase: Phase 2 · Conditions: Myeloma Multiple · Last updated: 2026-11-16

This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with multiple myeloma and have kidney failure? This study is being done because the investigators…

1 study locations, 1 in the United States (including Anchorage, Alaska).

View this trial on ClinicalTrials.gov (NCT07085728)

An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy

NCT06255223 · Status: Recruiting · Phase: Phase 2 · Conditions: Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor · Last updated: 2026-11-16

The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.

1 study locations, none listed in the United States (including Nanjing, Jiangsu).

View this trial on ClinicalTrials.gov (NCT06255223)

An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.

NCT07937553 · Status: Recruiting · Phase: Phase 2 · Conditions: Metastatic Chromophobe Renal Cell Carcinoma · Last updated: 2026-11-16

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC. Lenvatinib plus everolimus (LEN+EVE) has…

8 study locations, none listed in the United States (including Chelyabinsk, Russia; Krasnoyarsk, Russia; Orenburg, Russia).

View this trial on ClinicalTrials.gov (NCT07937553)

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function

NCT07938515 · Status: Recruiting · Phase: Phase 1 · Conditions: Obesity & Overweight · Last updated: 2026-11-16

This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal…

1 study locations, none listed in the United States (including Suzhou, Jiangsu).

View this trial on ClinicalTrials.gov (NCT07938515)

Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)

NCT04571658 · Status: Recruiting · Phase: Not applicable · Conditions: Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome · Last updated: 2026-11-16

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

16 study locations, 16 in the United States (including Atlanta, Georgia; Chicago, Illinois; Kansas City, Kansas).

View this trial on ClinicalTrials.gov (NCT04571658)

The Effects of Increased Water Intake on Muscle Function, Physical Performance, and Endocrine Regulation in Low-Drinking Older Adults: A Randomized Controlled Trial

NCT07892742 · Status: Recruiting · Phase: Not applicable · Conditions: Dehydrated, Water-Electrolyte Imbalance, Malnutrition, Dehydration (Physiology) · Last updated: 2026-11-16

Population aging represents one of the major demographic transformations of the 21st century. However, increased longevity has not been accompanied by preserved functional independence. Falls are currently the leading cause of injury-related mortality and a major contributor to hospitalization, disability, and…

1 study locations, none listed in the United States (including Rio Maior, Portugal).

View this trial on ClinicalTrials.gov (NCT07892742)

More from the Clinical Trials Finder

This page is general information only. It is not medical advice, it does not say whether any trial is right for you, and it makes no promise about eligibility or enrollment. Clinical trials have eligibility criteria set by the trial team, and taking part is always voluntary. Talk to your own care team before contacting any trial, and confirm every detail on the trial's own ClinicalTrials.gov page.